Blog Posts

5 Key Focus Areas in a 340B Audit

SPONSORED CONTENT

The phrase “we’re scheduling an audit” generally triggers angst, tension and even fear. Audits of your 340B operations look deeply into your prescription records and billing procedures. They are complex and require a great deal of preparation and

Read More »

340B Lobbying Activity Did Not Slow Down in Q3, Federal Filings Suggest

340B Working Table
More than 360 firms reported lobbying on the 340B program between July 1 and Sept. 30.
The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Total 340B Drug Purchases Reached $66 Billion in 2023

Total 340B purchases reached $66.3 billion in 2023, according to new HRSA data released Oct. 18.
Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Former Senior Trump Official Talks Drug Pricing Reform, Says 340B Program Is ‘Out of Control’

Joe Grogan (left), a top official in the former Trump administration raised serious concerns with the 340B program during the keynote address at The Association for Value-Based Cancer Care Annual Summit in New York Thursday.
A key official in the former Trump administration raised serious concerns with the 340B program during the keynote address at [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Former J&J Attorney and Current Kalderos Board Director Says Battle over Rebates Has Not Ended

J&J's proposed rebate model was a key topic of discussion at a Wednesday panel led by moderator, 340B Report Publisher and CEO Ted Slafsky.
An influential drug industry expert said that he expects Johnson & Johnson (J&J) to sue the government over its refusal [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Optimizing Your 340B Program: Ensuring Accurate Capture and Identifying Data Gaps

SPONSORED CONTENT

The 340B Drug Pricing Program offers significant savings to eligible healthcare organizations, enabling them to stretch scarce resources further and provide better services to their communities. However, ensuring your program captures the maximum potential savings and operates optimally requires close monitoring of

Read More »

Dark Money Poured Nearly $4M into Super PAC Opposing State 340B Contract Pharmacy Access Bills

Stand for US PAC received $3.8 million in contributions over the last three months from a conservative dark money group.
A political action committee (PAC) that funded efforts opposing state 340B contract pharmacy access bills through misleading claims linking the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

LA Times Says ‘No’ to California Ballot Measure That Would Affect 340B 

The Los Angeles Times’ editorial board endorsed the “no” position on Proposition 34, a 340B-realated measure which will appear on the Nov. 5 ballot.
An influential California newspaper recently urged against a November ballot measure, which would require certain healthcare providers in the state [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota

Key motions were recently filed in state contract pharmacy litigation in Missouri and Minnesota.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

PhRMA Pans Government’s Response to J&J’s 340B Rebate Proposal in Letter to HRSA Administrator

PhRMA sent an Oct. 11 letter to HRSA criticizing the agency's opposition to J&J's 340B rebate proposal.
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live